Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| 1 |
Apple
AAPL
|
+$564M |
| 2 |
UnitedHealth
UNH
|
+$439M |
| 3 |
Johnson & Johnson
JNJ
|
+$353M |
| 4 |
Amazon
AMZN
|
+$200M |
| 5 |
Microsoft
MSFT
|
+$198M |
Top Sells
| 1 |
EXE
Expand Energy Corporation Common Stock
EXE
|
+$344M |
| 2 |
JPMorgan Chase
JPM
|
+$293M |
| 3 |
Kellanova
K
|
+$165M |
| 4 |
SUM
Summit Materials, Inc. Class A Common Stock
SUM
|
+$159M |
| 5 |
AZPN
Aspen Technology Inc
AZPN
|
+$156M |
Sector Composition
| 1 | Technology | 18.85% |
| 2 | Financials | 18.69% |
| 3 | Industrials | 11.91% |
| 4 | Healthcare | 10.42% |
| 5 | Consumer Discretionary | 10.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2826
Caribou Biosciences
CRBU
$175M
| $1.26M | ﹤0.01% |
1,384,669
-347,709
| -20% | -$318K |
|
2827
Adverum Biotechnologies
ADVM
$70.1M
| $1.26M | ﹤0.01% |
287,794
-23,211
| -7% | -$101K |
|
2828
Richmond Mutual Bancorp
RMBI
$142M
| $1.25M | ﹤0.01% |
97,900
+4,692
| +5% | +$60.1K |
|
2829
GrowGeneration
GRWG
$90.3M
| $1.25M | ﹤0.01% |
1,158,191
-222,950
| -16% | -$241K |
|
2830
CleanSpark
CLSK
$2.85B
| $1.25M | ﹤0.01% |
186,035
-3,606,679
| -95% | -$24.2M |
|
|
NAGE
2831
Niagen Bioscience, Inc. Common Stock
NAGE
$765M
| $1.25M | ﹤0.01% |
181,099
+58,177
| +47% | +$401K |
|
2832
Cytokinetics
CYTK
$6.24B
| $1.25M | ﹤0.01% |
31,034
-63,090
| -67% | -$2.54M |
|
2833
Wolfspeed
WOLF
$264M
| $1.24M | ﹤0.01% |
406,861
-146,092
| -26% | -$446K |
|
2834
Citizens
CIA
$271M
| $1.24M | ﹤0.01% |
271,971
+2,390
| +0.9% | +$10.9K |
|
2835
Golar LNG
GLNG
$4.28B
| $1.24M | ﹤0.01% |
32,541
+15
| +0% | +$570 |
|
2836
Codexis
CDXS
$222M
| $1.23M | ﹤0.01% |
458,616
+52,641
| +13% | +$142K |
|
2837
Rubrik
RBRK
$15.8B
| $1.23M | ﹤0.01% |
20,199
-16,542
| -45% | -$1.01M |
|
2838
Grab
GRAB
$21.4B
| $1.23M | ﹤0.01% |
271,745
+50,097
| +23% | +$227K |
|
2839
Loar Holdings
LOAR
$7.53B
| $1.23M | ﹤0.01% |
17,406
+12,195
| +234% | +$862K |
|
|
GRAL
2840
GRAIL, Inc. Common Stock
GRAL
$1.29B
| $1.22M | ﹤0.01% |
47,911
-241
| -0.5% | -$6.16K |
|
2841
Monte Rosa Therapeutics
GLUE
$300M
| $1.22M | ﹤0.01% |
262,990
+118,179
| +82% | +$548K |
|
2842
Crexendo
CXDO
$194M
| $1.21M | ﹤0.01% |
247,506
+29,858
| +14% | +$145K |
|
2843
Alto Ingredients
ALTO
$89M
| $1.19M | ﹤0.01% |
1,046,231
-221,564
| -17% | -$253K |
|
2844
Chegg
CHGG
$179M
| $1.19M | ﹤0.01% |
1,865,988
-272,536
| -13% | -$174K |
|
2845
Symbotic
SYM
$5.5B
| $1.19M | ﹤0.01% |
58,905
+9,124
| +18% | +$184K |
|
2846
Union Bankshares
UNB
$117M
| $1.18M | ﹤0.01% |
37,486
+2,210
| +6% | +$69.6K |
|
2847
Full House Resorts
FLL
$121M
| $1.18M | ﹤0.01% |
282,168
-4,152
| -1% | -$17.4K |
|
2848
IonQ
IONQ
$13.1B
| $1.17M | ﹤0.01% |
53,238
+4,218
| +9% | +$93.1K |
|
2849
Rigel Pharmaceuticals
RIGL
$658M
| $1.17M | ﹤0.01% |
65,300
+48,177
| +281% | +$867K |
|
|
YSG
2850
Yatsen Holding
YSG
$942M
| $1.17M | ﹤0.01% |
242,082
+28,252
| +13% | +$136K |
|